Story perspectives

OpenAI and AbbVie Revolutionize Research with AI Innovations

5/13/2025

36 4

Summary

Story summary

OpenAI, led by chief scientist Jakub Pachocki, is pushing the boundaries of AI with innovative reasoning models aimed at scientific breakthroughs. Simultaneously, AbbVie harnesses AI to transform drug discovery, streamlining target identification and design through generative models. Together, these companies are showcasing AI's transformative power in research and development.

History

Historical Context

OpenAI and AbbVie are advancing AI in research and drug discovery, echoing trends from the 1990s when biotechnology firms began leveraging computational methods for drug development. This shift parallels the 2010s' rise of AI in healthcare, enhancing efficiency and innovation. Historical collaborations, like AbbVie's partnerships for oncology treatments, underscore the growing intersection of technology and pharmaceuticals, aiming to address complex health challenges.

1 of 2

Story summary

OpenAI, led by chief scientist Jakub Pachocki, is pushing the boundaries of AI with innovative reasoning models aimed at scientific breakthroughs. Simultaneously, AbbVie harnesses AI to transform drug discovery, streamlining target identification and design through generative models. Together, these companies are showcasing AI's transformative power in research and development.

1 / 2